Clinical Trial Update: To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors [Phase 1, Phase 2]

View source ↗

Summary

This update reports the completion of a Phase I/II clinical trial evaluating XNW5004 tablets in patients with relapsed/refractory advanced solid tumors and lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• XNW5004

Snippet

Sponsor: Evopoint Biosciences Inc. | Conditions: Advanced Tumor, Lymphoma | Phase 1, Phase 2 | Status: COMPLETED